Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating…
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recursion Gains European Commission Orphan Drug Status For Rare Tumor Candidate
Recursion (NASDAQ: RXRX) received Orphan Drug Designation for REC-4881 from the European Commission towards the potential treatment of familial adenomatous polyposis (FAP).
Bionano Genomics Highlights Publication Of Study Using OGM To Investigate Chromosome Instability
Bionano Genomics, Inc. (NASDAQ:BNGO), today announced publication of a study using optical genome mapping (OGM) to investigate numerical and structural changes to two induced pluripotent stem cell (iPSC) lines,
X4 Pharma To Stop Further Work On Oncology Programs, Looks For Partner(s)
X4 Pharmaceuticals Inc (NASDAQ:XFOR) updated its strategic priorities that include streamlining resources to focus on advancing its lead candidate, mavorixafor, in…
Incannex Receives Ethics Approval To Commence Phase 1 Clinical Trial Of Multi-Use Anti-Inflammatory Drug IHL-675A
Highlights:
Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of IHL-675A on July 20, 2022
The trial will be performed at CMAX Clinical
Olema Oncology Receives FDA Fast Track Designation For OP-1250 For Treatment Of ER+ / HER2- Metastatic Breast Cancer
Olema Pharmaceuticals, Inc. ((&ldquo, Olema&rdquo, or &ldquo, Olema Oncology, &rdquo, NASDAQ:OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250, the
Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection
Assembly Biosciences Inc (NASDAQ:ASMB) will stop working on its first-generation core inhibitor, vebicorvir (VBR), as it prioritizes its next-gen core…
Biogen Reveals $900M Settlement In Whistleblower’s MS Drug Kickbacks Lawsuit Days Before Trial
Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlemen
